Login
MYRIAD GENETICS INC logo

MYRIAD GENETICS INC

myriad.com

What Do They Do?

Sells molecular tests that assess disease risk and help healthcare providers choose treatments for patients across cancer care, prenatal screening and mental health.

How Do They Make Money?

Myriad earns money by processing molecular tests and billing customers when each test is completed and its results are released to a healthcare provider or patient.

revenue
SegmentShareRevenue
Hereditary Cancer
Sold outright

45%
FY2022: 45%
Tumor Profiling
Sold outright

15%
FY2022: 19%
Prenatal
Sold outright

23%
FY2022: 17%
Mental Health
Sold outright

17%

Who Are Their Customers?

Patients and healthcare providers use Myriad's tests. The company sells primarily through its sales force in the United States and Japan, while indirect channels and partnerships extend its reach in Europe and Asia-Pacific.

Customers above 10% of revenue, FY2025
of revenue from one customer
FY2023: 12% from one customer

Do Revenues Turn Into Profits?

No. It lost $365.9M in FY2025.

Operating income, FY2025
−47% of revenue
▼ −214% (Loss) vs FY2024 (−$123.5M, −15%)
Net income, FY2025
−44% of revenue
▼ −187% (Loss) vs FY2024 (−$127.3M, −15%)
Free cash flow, FY2025
−2% of revenue
▲ +50% (Loss) vs FY2024 (−$27.7M, −3%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −1%
vs $205.7M in Q3 FY2025
Net income
▼ −60% (Loss)
vs −$27.4M in Q3 FY2025
  • Nov 4, 2026 Raised midpoint of full-year revenue guidance The company cited third-quarter results and current business trends for the rest of the year.
  • Oct 19, 2026 Agreed to sell Prenatal Health business to Labcorp The deal covers Foresight, Prequel, FirstGene and SneakPeek and remains subject to closing conditions.

Growing. Revenue grew 19% in 4 years, from $690.6M in FY2021 to $824.5M in FY2025, about 5% a year.

EndoPredict sale The older report described EndoPredict as a Myriad test; the latest says the business was divested to Eurobio, with Myriad retaining sales rights outside the European Union under license.

Cancer monitoring The older report described Precise MRD as planned for research use only; the latest describes a tumor-informed test for monitoring tumor DNA through cancer care and surveillance.

Prenatal screening FirstGene moved from a planned launch to limited early access: the latest report describes a single assay combining several prenatal testing methods.

Revenue over time
Hereditary Cancer Tumor Profiling Prenatal Mental Health Other Autoimmune Pharmacogenomics Other revenue
$1B$500M$0

Who Do They Compete With?

Competes with Natera, Foundation Medicine, Caris Life Sciences, Tempus, Laboratory Corporation of America, Quest Diagnostics, Veracyte, Guardant Health, MDxHealth, NeoGenomics, BillionToOne, Fulgent Genetics, and Genomind

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support